期刊文献+

处方级联一例分析 被引量:2

Analysis of prescription cascade:a case report
原文传递
导出
摘要 1例90岁高血压患者因头晕就诊于基层医院,应用盐酸阿罗洛尔片3 h后出现心动过缓。对症给予硫酸阿托品注射液0.25 mg入壶,未出现不适,7 h后再次给予0.5 mg后出现排尿困难、尿潴留,提示处方级联形成。临床药师及时发现,建议停药,对症处理后好转,2 d后排尿正常。提示社区医务人员需重视处方级联,以及基层药师需要探索基于社区的药物治疗管理服务,在药物选择时注意预防处方级联,保障患者用药安全。 A 90-year-old patient with hypertension went to primary hospital for dizziness.The patient developed bradycardia 3 hours after administration of Arotinolol.0.25 mg Atropine was given to the patient and discomfort was not found.0.5 mg Atropine was given again 7 hours later.The patient developed dysuria and retention of urine,suggesting a cascade of prescriptions.The clinical pharmacist promptly discovered the medication problem and advised to stop the medicine.After the symptomatic treatment,patient got improved.The micturition got recovered 2 days later.This case suggests that the medical staffs in our community should pay more attention to the prescription cascade.Pharmacists working at primary care institutions need to explore community-based drug treatment management and pay attention to the prescription cascade in order to improve medication safety.
作者 黄茜 陈常凤 史亦丽 HUANG Xi;CHEN Chang-feng;SHI Yi-li(Department of Pharmacy,Beijing Airport Hospital,Beijing 101318,China;Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)
出处 《临床药物治疗杂志》 2022年第5期78-79,共2页 Clinical Medication Journal
关键词 盐酸阿罗洛尔 硫酸阿托品 尿潴留 处方级联 Arotinolol Atropine urinary retention prescription cascade
  • 相关文献

参考文献5

二级参考文献60

  • 1刘国仗.阿罗洛尔上市后多中心监测研究.高血压杂志,2005,13:56-58.
  • 2杨宝峰.药理学[M].8版.北京:人民卫生出版社,2013:1-484.
  • 3James PA, Oparil S, Carter BI., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint na- tional committee (JNC8)[J]. JAMA,2014,311(5) :507-520.
  • 4Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014)[J]. Hypertens Res,2014,37(4) :253-390.
  • 5Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the Europe- an Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. Eur Heart J,2013,34(28):2159- 2219.
  • 6Fang H, Chen W, Liu X, et al. The efficacy and safety of aroti- nolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension:a one year follow-up study[J]. Clin Exp Hypertens, 2014,36 (8) : 590- 595.
  • 7Zhou W, Hong M, Zhang K, et al. Mechanisms of improved aor- tic stiffness by arotinolol in spontaneously hypertensive rats[J]. PLoS One,2014,9(2) :e88722.
  • 8Dhakam Z, Yasmin, McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension[J]. J Hypertens,2008,26(2) :351-356.
  • 9van Zwieten PA. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenocep- tot antagonists[J]. Drugs,1993,45(4):509-517.
  • 10Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders[J]. Drugs,1997,54(1) : 161-185.

共引文献167

同被引文献16

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部